Reduced cholesterol absorption upon PPAR activation coincides with decreased intestinal expression of NPC 1 L 1

Peroxisome proliferator-activated receptors (PPARs) control the transcription of genes involved in lipid metabolism. Activation of PPAR may have antiatherogenic effects through the increase of plasma HDL, theoretically promoting reverse cholesterol transport from peripheral tissues toward the liver for removal via bile and feces. Effects of PPAR activation by GW610742 were evaluated in wild-type and Abca1-deficient ( Abca1 / ) mice that lack HDL. Treatment with GW610742 resulted in an 50% increase of plasma HDL-cholesterol in wild-type mice, whereas plasma cholesterol levels remained extremely low in Abca1 / mice. Yet, biliary cholesterol secretion rates were similar in untreated wild-type and Abca1 / mice and unaltered upon treatment. Unexpectedly, PPAR activation led to enhanced fecal neutral sterol loss in both groups without any changes in intestinal Abca1 , Abcg5 , Abcg8 , and 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression. Moreover, GW610742 treatment resulted in a 43% reduction of fractional cholesterol absorption in wild-type mice, coinciding with a significantly reduced expression of the cholesterol absorption protein NiemannPick C1-like 1 ( Npc1l1 ) in the intestine. PPAR activation is associated with increased plasma HDL and reduced intestinal cholesterol absorption efficiency that may be related to decreased intestinal Npc1l1 expression. Thus, PPAR is a promising target for drugs aimed to treat or prevent atherosclerosis. —van der Veen, J. N., J. K. Kruit, R. Havinga, J. F. W. Baller, G. Chimini, S. Lestavel, B. Staels, P. H. E. Groot, A. K. Groen, and F. Kuipers. Reduced cholesterol absorption upon PPAR activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res. 2005. 46: 526–534. Supplementary key words Niemann-Pick C1-like 1 • peroxisome proliferator-activated receptor • nuclear receptors • high density lipoprotein-cholesterol Plasma levels of HDL-cholesterol are inversely related to the development of atherosclerosis (1). This protective effect has been attributed to a role of HDL in reverse cholesterol transport (RCT), defined as the flux of excess cholesterol from peripheral cells to nascent HDL particles followed by transport to the liver. The liver is able to secrete cholesterol into bile, either as free cholesterol or after conversion into bile salts, for removal via the feces. Stimulation of HDL-mediated cholesterol efflux is considered an attractive approach to diminish the development of atherosclerosis. ABCA1 is considered to be essential in RCT (2). ABCA1 is ubiquitously expressed and probably involved in the formation of pre -HDL particles and the efflux of cholesterol from peripheral tissues toward HDL (3). HDL is considered a major source for bile-destined cholesterol (4). However, we recently demonstrated that, despite the absence of HDL, hepatobiliary cholesterol flux and fecal sterol excretion are not affected in Abca1-deficient ( Abca1 / ) mice (5, 6). The ABCG5/ABCG8 heterodimer was recently shown to be of crucial importance for hepatobiliary cholesterol secretion and for transport of cholesterol from enterocytes back into the intestinal lumen, thereby promoting net cholesterol removal from the body (7, 8). Several genes involved in the control of cholesterol meAbbreviations: Abca1 / , Abca1-deficient; FPLC, fast-protein liquid chromatography; Hmgr, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; Mdr2, multidrug resistance P-glycoprotein 2; NPC1L1, Niemann-Pick C1-like 1; Pdk4, pyruvate dehydrogenase kinase isoenzyme 4; PPAR, peroxisome proliferator-activated receptor; RCT, reverse cholesterol transport; Sr-b1, scavenger receptor B1. 1 To whom correspondence should be addressed. e-mail: j.n.van.der.veen@med.rug.nl 2 J. N. van der Veen and J. K. Kruit contributed equally to this work. Manuscript received 12 October 2004 and in revised form 23 November 2004. Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400400-JLR200 at P E N N S T A T E U N IV E R S IT Y , on F ebuary 3, 2013 w w w .j.org D ow nladed fom

[1]  Jianjun Liu,et al.  Niemann-Pick C1 Like 1 (NPC1L1) Is the Intestinal Phytosterol and Cholesterol Transporter and a Key Modulator of Whole-body Cholesterol Homeostasis* , 2004, Journal of Biological Chemistry.

[2]  E. Dennis,et al.  Journal of Lipid Research , 2003, Journal of Lipid Research.

[3]  F. Kuipers,et al.  Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. , 2003, Journal of hepatology.

[4]  H. Brewer,et al.  Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations Published, JLR Papers in Press, November 4, 2002. DOI 10.1194/jlr.M200414-JLR200 , 2003, Journal of Lipid Research.

[5]  B. Staels,et al.  Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. , 2003, The Biochemical journal.

[6]  J. Repa,et al.  Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200144-JLR200 , 2002, Journal of Lipid Research.

[7]  A. Tall,et al.  Regulation and mechanisms of macrophage cholesterol efflux. , 2002, The Journal of clinical investigation.

[8]  M. Smit,et al.  Increased Hepatobiliary and Fecal Cholesterol Excretion upon Activation of the Liver X Receptor Is Independent of ABCA1* , 2002, The Journal of Biological Chemistry.

[9]  B. Staels,et al.  The role of PPARs in atherosclerosis. , 2002, Trends in molecular medicine.

[10]  Jonathan C. Cohen,et al.  Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. , 2002, The Journal of clinical investigation.

[11]  J. Dietschy,et al.  Control of Cholesterol Turnover in the Mouse* , 2002, The Journal of Biological Chemistry.

[12]  H. Davis,et al.  Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in ApoE Knockout Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[13]  O. Francone,et al.  Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. , 2001, The Journal of clinical investigation.

[14]  B Staels,et al.  Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator–Activated Receptor-&agr;–Mediated Downregulation of Cholesterol 7&agr;-Hydroxylase and Sterol 27-Hydroxylase Expression , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[15]  D. Russell,et al.  Alternate pathways of bile acid synthesis in the cholesterol 7alpha-hydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding. , 2001, Journal of lipid research.

[16]  H. Bays,et al.  Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. , 2001, Clinical therapeutics.

[17]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  F. Kuipers,et al.  Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL. , 2001, The Journal of clinical investigation.

[19]  T. V. van Berkel,et al.  Low density lipoprotein receptor of macrophages facilitates atherosclerotic lesion formation in C57Bl/6 mice. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[20]  C. Gabel,et al.  High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Sensen,et al.  Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency , 1999, Nature Genetics.

[22]  F. Kuipers,et al.  Reduced plasma cholesterol and increased fecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice. , 1998, Gastroenterology.

[23]  J. Dietschy,et al.  Reevaluation and application of the dual-isotope plasma ratio method for the measurement of intestinal cholesterol absorption in the hamster. , 1994, Journal of lipid research.

[24]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[25]  D. H. Gregory,et al.  Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man. , 1978, Science.

[26]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[27]  F. Kuipers,et al.  Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. , 2005, Gastroenterology.

[28]  T. Willson,et al.  Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity. , 2003, Bioorganic & medicinal chemistry letters.

[29]  Luquan Wang,et al.  Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption , 2022 .